Draper Associates

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026

Draper Associates is a global venture firm investing in AI, robotics, blockchain, healthcare, biotechnology, aerospace and other emerging technologies.

Its blockchain thesis includes decentralised finance, tokenised assets and decentralised infrastructure. In healthcare, it focuses on technologies such as AI diagnostics, regenerative medicine and neurotechnology that can improve prevention and healthy lifespan.

The firm also backs automation and human-machine collaboration, alongside space technologies. Founders can submit a pitch directly through its website, which also provides an AI pitch-coaching tool.

Sources
Rounds participated in
4
Confirmed lead rounds
0
2 roles undisclosed
New companies
4
First participation on record · 0 follow-on
Funding in participating rounds
$92.4M
3 disclosed · full round size, not this investor’s share

By stage

Series A2
Seed1
Undisclosed1

By primary sector

Biotech2
AI1
Industrial tech1

By country

United States3
United Kingdom1

Rounds

4 in this selection
Cloverleaf Bio

Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical.

$33MSeed
Participant
Syntax Bio

Develops cell therapies using proprietary Cellgorithm platform for regenerative medicine

$14.4MSeries A+
Role not disclosed
Apoha

Apoha measures molecular behavior for pharmaceutical, food and materials research.

UndisclosedSeries A
Participant
Ten63 Therapeutics

Develops AI-driven drug discovery platform for first- and best-in-class therapeutics

$45MStrategic
Role not disclosed